Literature DB >> 19381774

Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson's disease in a Swedish population.

H Niazi Shahabi1, L Westberg, J Melke, A Håkansson, A Carmine Belin, O Sydow, L Olson, B Holmberg, H Nissbrandt.   

Abstract

Cytochrome P450 2E1 (CYP2E1), which inter alia is located in dopamine containing neurons in the substantia nigra, has been hypothesized to be of importance for the pathophysiology of Parkinson's disease (PD), either by its production of reactive oxygen species (ROS) or by its capability to detoxify putative neurotoxins. Numerous polymorphisms in the coding and non-coding regions of the gene for this enzyme have been reported. Different variants may account for inter-individual differences in the activity of the enzyme or production of ROS. In this study, the CYP2E1 gene was examined in a control population (n = 272) and a population with PD (n = 347), using a tag-single nucleotide polymorphism (tSNP) approach founded on HapMap Data. Six tSNPs were used in the analysis and haplotype block data were obtained. In case of significance, the SNP was further examined regarding early/late age of disease onset and presence of relatives with PD. We found an association between allele and genotype frequencies of the C/G polymorphism at intron 7 (rs2070676) of this gene and PD (P value of 0.026 and 0.027, respectively). Furthermore, analysis of the rs2070676 polymorphism in subgroups of patients with age of disease onset higher than 50 years and those not having a relative with PD also demonstrated a significant difference with controls. This was seen in both genotype (corresponding to P value = 0.039 and 0.032) and allele (P = 0.027 and 0.017 respectively) frequency. As a representative of many polymorphisms or in possible linkage disequilibrium with other functional variants, it is possible that rs2070676 could influence the regulation of the enzyme. In conclusion, our results display an association between the rs2070676 polymorphism and PD. Additional investigations are needed to elucidate the importance of this polymorphism for the activity of CYP2E1 and PD susceptibility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381774     DOI: 10.1007/s00702-009-0221-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  51 in total

1.  Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity.

Authors:  C Viaggi; C Pardini; F Vaglini; G U Corsini
Journal:  J Neural Transm Suppl       Date:  2006

2.  Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.

Authors:  P M Watts; A G Riedl; D C Douek; R J Edwards; A R Boobis; P Jenner; C D Marsden
Journal:  Neuroscience       Date:  1998-09       Impact factor: 3.590

3.  Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.

Authors:  H H Liou; M C Tsai; C J Chen; J S Jeng; Y C Chang; S Y Chen; R C Chen
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

4.  The role of NADH in uncoupled microsomal monoxygenations.

Authors:  H Staudt; F Lichtenberger; V Ullrich
Journal:  Eur J Biochem       Date:  1974-07-01

5.  Catalytic activity and quantitation of cytochrome P-450 2E1 in prenatal human brain.

Authors:  M R Brzezinski; H Boutelet-Bochan; R E Person; A G Fantel; M R Juchau
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

6.  RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma.

Authors:  J M Ladero; J A Agúndez; A Rodríguez-Lescure; M Diaz-Rubio; J Benítez
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

Review 7.  P450 enzymes and Parkinson's disease: the story so far.

Authors:  A G Riedl; P M Watts; P Jenner; C D Marsden
Journal:  Mov Disord       Date:  1998-03       Impact factor: 10.338

8.  Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production.

Authors:  H Niazi Shahabi; D R Andersson; H Nissbrandt
Journal:  Synapse       Date:  2008-05       Impact factor: 2.562

Review 9.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

10.  Detection and characterization of novel polymorphisms in the CYP2E1 gene.

Authors:  K S Fairbrother; J Grove; I de Waziers; D T Steimel; C P Day; C L Crespi; A K Daly
Journal:  Pharmacogenetics       Date:  1998-12
View more
  14 in total

1.  HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs.

Authors:  J Robert Chang; Ruma Mukerjee; Asen Bagashev; Luis Del Valle; Tinatin Chabrashvili; Brian J Hawkins; Johnny J He; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

2.  APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

3.  Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1.

Authors:  Oliver Kaut; Ina Schmitt; Ullrich Wüllner
Journal:  Neurogenetics       Date:  2012-01-12       Impact factor: 2.660

Review 4.  Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1.

Authors:  P S S Rao; Narasimha M Midde; Duane D Miller; Subhash Chauhan; Anil Kumar; Santosh Kumar
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

5.  HIV-1 Tat C-mediated regulation of tumor necrosis factor receptor-associated factor-3 by microRNA 32 in human microglia.

Authors:  Ritu Mishra; Chintan Chhatbar; Sunit Kumar Singh
Journal:  J Neuroinflammation       Date:  2012-06-18       Impact factor: 8.322

6.  Acetaldehyde and parkinsonism: role of CYP450 2E1.

Authors:  Francesca Vaglini; Cristina Viaggi; Valentina Piro; Carla Pardini; Claudio Gerace; Marco Scarselli; Giovanni Umberto Corsini
Journal:  Front Behav Neurosci       Date:  2013-06-21       Impact factor: 3.558

Review 7.  The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain.

Authors:  W A García-Suástegui; L A Ramos-Chávez; M Rubio-Osornio; M Calvillo-Velasco; J A Atzin-Méndez; J Guevara; D Silva-Adaya
Journal:  Oxid Med Cell Longev       Date:  2017-01-10       Impact factor: 6.543

8.  K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt.

Authors:  Thomas W Rösler; Mohamed Salama; Ali S Shalash; Eman M Khedr; Abdelhalim El-Tantawy; Gharib Fawi; Amal El-Motayam; Ehab El-Seidy; Mohamed El-Sherif; Mohamed El-Gamal; Mohamed Moharram; Mohammad El-Kattan; Muhammad Abdel-Naby; Samia Ashour; Ulrich Müller; Astrid Dempfle; Gregor Kuhlenbäumer; Günter U Höglinger
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

9.  Gene expression responses to FUS, EWS, and TAF15 reduction and stress granule sequestration analyses identifies FET-protein non-redundant functions.

Authors:  Jenny Blechingberg; Yonglun Luo; Lars Bolund; Christian Kroun Damgaard; Anders Lade Nielsen
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

Review 10.  Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases.

Authors:  Oscar Teijido; Ramón Cacabelos
Journal:  Int J Mol Sci       Date:  2018-10-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.